The US Food and Drug Administration (FDA) recently approved lutetium Lu 177 vipivotide tetraxetan (also known by the trade name PLUVICTO®) for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor pathway inhibitor (ARPI) therapy and who are considered appropriate to delay…